Printing an Organ? The Hard Part Isn't the Printer — It's Keeping It Alive

A photograph of a printed 'heart' or 'kidney' reads like a preview of the day we print organs to order. Why print an organ at all? Transplant organs are always in short supply, and building one from a patient's own cells sidesteps immune rejection. That promise has pulled this technology along for more than twenty years. Yet across all those repeating demos, the number of printed parenchymal organs — thick solid organs like the heart, liver, kidney, and lung that only stay alive if blood runs through vessels inside them — implanted into a patient is still zero. The obstacle isn't the printer. Placing cells in the shape you want mostly works. Keeping the placed cells alive does not. This piece follows the plumbing underneath — how you print, what gets built, what still doesn't and why, how the field means to break through the wall, and where it goes.

How You Print Cells

Bioprinting is additive manufacturing that stacks cells into a chosen three-dimensional arrangement. There are broadly three ways to lay cells down, and none of them satisfies resolution, cell survival, and density at once — each trades one against the others. Inkjet (spraying a cell-laden fluid as droplets) is fast and cheap but handles only thin inks and reaches low density (<10^6 cells/ml). Extrusion (squeezing a gel through a nozzle) is the only route that carries cells to physiological density, but the cells are crushed passing through the nozzle, giving it the lowest survival rate at 40–80%. Laser (flicking cells across with a pulse) has the best survival (>95%) and resolution but low throughput and high cost.

The cells come out suspended in a 'bioink' — a formulation that carries cells through printing. Its main material is a hydrogel (a water-swollen polymer gel — GelMA, alginate, collagen, and the like). Here too there is a trade-off. The denser and stiffer you make the gel, the better it holds its shape — but that tight mesh blocks the cells from surviving, spreading, and migrating. The narrow band where the two overlap is called the 'biofabrication window.'

The source of the cells is a problem too. To avoid immune rejection you use the patient's own cells or iPSCs (induced pluripotent stem cells — a patient's cells reverted to a pluripotent state). The bottleneck at this stage, again, isn't the printer but securing enough functional cells that have differentiated (a stem cell maturing into a specific functional cell type). Native parenchymal tissue is dense — around 10^8 cells/ml (the liver, for one) — and printing usually falls short of that.

Printing isn't the end. Freshly printed tissue is immature. You place it in a perfusion bioreactor (a device that cultures the construct by flowing medium through it) to deliver nutrients and oxygen evenly and mature the cells with mechanical stimulation. But the link between mechanical stimulation and maturation isn't yet established, so the bioreactor stays a 'pre-implantation conditioning tool.'

What Gets Built, and What Still Doesn't

The single word 'bioprinting' lumps together technologies at wildly different levels of maturity. One axis separates them: how thick the tissue is.

Thin avascular tissue is closest to the clinic. When the tissue is thin, cells stay alive on oxygen seeping in from the surroundings alone. No vessels needed. Skin, cornea, and cartilage belong here. But note one thing. Most of these tissues that have reached the clinic are not printed. Skin sheets, engineered corneas, and hand-seeded bladders were made without printing. Among them, the one representative that reached a first-in-human trial (Phase 1/2a) as an actual 3D bioprint is a single case of ear cartilage (AuriNovo — a microtia patient's ear printed from the patient's own cells and implanted, first implant in 2022).

Tissue models and organ-on-chip (culturing cells in microchannels on a chip to mimic part of an organ's function) have reached the lab bench. They bypass the vessel problem entirely. A lung-on-chip, for instance, flows medium through two microchannels separated by a thin porous membrane, keeping cells alive with external microfluidics instead of vessels of their own. But a standard organ-on-chip like this is a microfabricated object made by soft lithography, not a bioprint. Bioprinting is only now entering this territory, and 'go small to go around' should be read as a field-level strategy, not a particular fabrication method.

Thick parenchymal organs are far off. The count of thick, metabolically demanding solid organs — the heart, liver, kidney — printed and implanted is zero. The axis that separates these three tiers converges on one thing: how far oxygen reaches.

Table sources: ear cartilage AuriNovo Phase 1/2a first-in-human trial (3DBio Therapeutics, 2022) · lung-on-chip (Huh et al., Science 2010) · zero printed parenchymal organs implanted (cross-checked across multiple reviews incl. Cureus 2025, as-of 2025-11) · oxygen diffusion limit ~100–200μm.

The Real Wall: Oxygen Travels Only 0.2mm

Cells take oxygen from blood vessels. But oxygen diffuses from a vessel into tissue only about 100–200μm — that is, 0.1–0.2mm (the oxygen diffusion limit). In metabolically active tissue, every cell must sit within that distance of its nearest vessel.

Thin tissue satisfies this condition on its own. Thick parenchymal organs do not. Once thickness exceeds the diffusion limit, the cells at the core get no oxygen or nutrients and drown in waste. Without a perfusable vascular network laid down inside — perfusion being the act of actually flowing fluid through the vessel network — the core rapidly undergoes necrosis and leaves a dead center: a necrotic core. Miller 2012 measured this directly. A gel with perfusion channels held its hepatocytes' metabolic function (albumin and urea production) through day 8, whereas an equal-volume gel with no channels lost that function — and the higher the density, the worse it got.

This is the crux. The bottleneck is not printer resolution but plumbing. Even if you solve placing cells at sufficient density, or maturing the tissue, without a perfusable vascular network this physics stays exactly where it is.

Vascularization (embedding a vascular network inside the tissue to carry oxygen and nutrients) is not the only wall. The latest reviews name three unsolved bottlenecks blocking thick organs: vascularization; scale and speed (two to three weeks for a single human-sized prototype); and functional maturation (printed liver tissue reaches only about 20% of the metabolic activity of real hepatocytes). Add to these the cell sourcing and maturation conditioning seen earlier. Even so, vascularization sits physically furthest upstream. Without perfusion the core cells die, and once the cells die there is no tissue left to mature and none to grow. Living tissue is the precondition for the other bottlenecks to even apply, and perfusion is precisely the condition that keeps that tissue alive.

Two Ways Over the Wall: Around It and Head-On

The field handles this wall along two lines.

Around it. The path that reaches the clinic and the bench by dodging the wall. Go thin (avascular tissue) and cells live on diffusion alone. Go small (organ-chip) and external microfluidics stand in for vessels. Regulation opened its door to this bypass route first. In 2022 the U.S. FDA Modernization Act 2.0 removed the single mandate that every new drug pass through animal testing, and recognized non-animal alternatives like organ-chips as valid evidence.

Head-on. The path that means to break through the wall by building the vascular network directly. There are two routes, opposite in method.

Table sources: Miller et al., Nature Materials 2012 · Grigoryan et al., Science 2019.

The two routes in the table share a goal and run opposite in method. One takes vessels away (the sacrificial template — printing a structure meant to be removed later, then dissolving and rinsing it out); the other puts vessels in (stereolithography that cures a hydrogel with light, SLATE) — both aiming to arrive at the same place. What joins them is not a particular technique but the goal of a perfusable vascular network, and the fact that Miller is the senior author of the Grigoryan paper, from the same lab, reveals that lineage. The progress is real, yet neither has reached thick parenchymal organs. Even Grigoryan's alveolus is a model that demonstrated perfusion, not an implanted organ.

Outlook: What Tells Us the Wall Has Been Breached

The trajectories split by maturity. Thin avascular tissue expands into the clinic incrementally. Organ-chips are already settled on the bench, and whether drug-screening adoption grows is one signal to watch. Another is how far vessel resolution and density climb in the sacrificial and direct-photoprinting lineage.

Thick parenchymal organs are different. Current reviews put a heart clinical trial at 2035 at the earliest. Landing that outlook in a falsifiable form: if a vascular network that is perfusable and anastomoses with host vessels (anastomosis — connecting the implanted tissue's vessels to the body's own) is demonstrated in a thick (>1cm) printed tissue in a large animal between 2030 and 2035, that is the first sign the wall has begun to break. Until that paper lands, 'organs in ten years' is, before it is an overstatement, an honest statement of an unsolved problem.

The litmus test must be read in two parts. The large-animal perfusion demonstration above is a signal that points directly at whether vascularization is being solved. 'Printed parenchymal organs implanted = still zero,' by contrast, is a far coarser indicator. That zero holds whether the cause is vascularization, scale and speed, functional maturation, or anything else. Reading it as 'zero, therefore it's vascularization' is over-interpretation. The zero is only an outcome; it does not pin down the cause.

In Korea, T&R Biofab and Rokit Healthcare chase this technology with dECM (decellularized extracellular matrix — the support scaffold left after cells are stripped from tissue) bioinks and scaffolds. The lens of tickers and valuation lives in Revenue Up 5.5×, a 34.9bn KRW Net Loss — What Does T&R Biofab Actually Earn On?; this piece's lens is the technical substance.

The printer already prints the shape. One question remains: when can we run blood through the printed tissue and keep it alive? Long before that answer arrives, the microfluidic organ models that went around the wall have begun to change how new drugs are tested.